Scarica l'app Stockscreener
10.71
6.79%
-0.78
Precedente Chiudi:
$11.49
Aprire:
$11.51
Volume 24 ore:
864.62K
Relative Volume:
1.03
Capitalizzazione di mercato:
$613.29M
Reddito:
-
Utile/perdita netta:
$-52.79M
Rapporto P/E:
-13.75
EPS:
-0.7789
Flusso di cassa netto:
$-53.49M
1 W Prestazione:
-3.82%
1M Prestazione:
-0.83%
6M Prestazione:
+131.82%
1 anno Prestazione:
+743.31%
Intervallo 1D:
$10.71
$11.79
Intervallo di 1 settimana:
$10.64
$11.87
Portata 52W:
$1.16
$12.48
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
10.71 | 657.95M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Mizuho | Outperform |
| 2026-03-24 | Iniziato | B. Riley Securities | Buy |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-11 | Iniziato | Raymond James | Strong Buy |
| 2026-03-05 | Iniziato | Wedbush | Outperform |
| 2026-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | William Blair | Outperform |
| 2025-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-08-15 | Iniziato | Robert W. Baird | Outperform |
| 2025-06-06 | Iniziato | Oppenheimer | Outperform |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Climb Bio Inc Borsa (CLYM) Ultime notizie
Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN
Why is Climb Bio stock gaining Friday? - MSN
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $17 - Moomoo
Climb Bio launches $100M at-the-market common stock offering - scanx.trade
Climb Bio Establishes New At-the-Market Equity Program - TipRanks
Climb BioEnters Open Market Sale Agreement With JefferiesSEC Filing - TradingView
Climb Bio Launches $100 Million ATM Equity Program With Jefferies - TradingView
CLYM Reiterates by Wedbush -- Price Target Maintained at $17.00 - GuruFocus
Why Is Climb Bio Stock Gaining Friday? - Benzinga
BTIG raises Climb Bio stock price target to $20 on ITP trial data - Investing.com UK
Climb Bio, Inc. reports initial Phase 1b data show robust B cell depletion in ITP trial - Traders Union
Climb Bio reports positive initial Phase 1b data for budoprutug in ITP - grafa.com
Climb Bio (CLYM) Shows Promising Results in Phase 1b Trial for B - GuruFocus
Climb Bio reports initial trial data for ITP treatment budoprutug - Investing.com UK
Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP - Moomoo
Climb Bio Reports Encouraging Early Budoprutug ITP Data - TipRanks
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio reports initial trial data for ITP treatment budoprutug By Investing.com - Investing.com Canada
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Climb Bio Announces Initial Phase 1b Data Demonstrating - GlobeNewswire
CLYM Stock Price, Quote & Chart - ChartMill
[EFFECT] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio (CLYM) files resale prospectus for 11.59M shares, including 2.106M warrant shares - Stock Titan
CLYM Initiates Coverage On by Guggenheim -- Rating Set at Buy - GuruFocus
Climb Bio (CLYM) reports 40,000-share option grant tied to RA Capital - Stock Titan
Climb Bio (CLYM) director Judith Dunn receives 40,000 stock options grant - Stock Titan
Director at Climb Bio (NASDAQ: CLYM) granted 40,000 options - Stock Titan
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (CLYM) awards director Douglas Williams 40,000 stock options - Stock Titan
Climb Bio (CLYM) director Alexander Cumbo awarded options on 40,000 shares - Stock Titan
Climb Bio (CLYM) director awarded 40,000 stock options grant - Stock Titan
Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors - TipRanks
Climb Bio shareholders elect directors and approve equity plan amendment By Investing.com - Investing.com Nigeria
Climb Bio shareholders elect directors and approve equity plan amendment - Investing.com
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
CLYM Reiterated by BTIG -- Price Target Maintained at $19.00 - GuruFocus
Guggenheim initiates Climb Bio stock coverage with buy rating By Investing.com - Investing.com South Africa
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Guggenheim initiates Climb Bio stock coverage with buy rating - Investing.com
Guggenheim Initiates Climb Bio at Buy With $35 Price Target - Moomoo
CLYM News | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail
Climb Bio reports initial safety data for CLYM116 in IgAN trial By Investing.com - Investing.com South Africa
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio stock dips despite initial CLYM116 safety data - Investing.com India
Climb Bio stock dips despite initial CLYM116 safety data By Investing.com - Investing.com Nigeria
Climb Bio Reports Positive Early-Stage Data for CLYM116 - TipRanks
Climb Bio reports initial safety data for CLYM116 in IgAN trial - Investing.com Australia
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Climb Bio, Inc. to Present CLYM116 Clinical Data and Development Plans at R&D Spotlight, Dosing in IgAN Patients Set to Begin Q3 2026 - Quiver Quantitative
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development - The Manila Times
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Climb Bio Inc Azioni (CLYM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):